Nurx IPO
Nurx was a telemedicine company focused on reproductive health, providing online consultations and prescription delivery for birth control, STI testing, and other women's health services. The company was part of the broader digital health trend that attracted significant investor interest before being acquired.
What We Know
Nurx was acquired by Thirty Madison in March 2022 for an undisclosed amount. The acquisition combined Nurx's reproductive health platform with Thirty Madison's portfolio of direct-to-consumer healthcare brands, creating a larger digital health company. Prior to the acquisition, Nurx had raised over $130 million in venture funding and was considered a potential IPO candidate in the telemedicine space. However, like many digital health companies, Nurx faced challenges with unit economics and regulatory complexities in the telehealth market, ultimately leading to the strategic sale to Thirty Madison rather than pursuing a public offering.
Frequently Asked Questions
Has Nurx had an IPO?
No, Nurx never had an IPO. The company was acquired by Thirty Madison in 2022 before going public.
When is the Nurx IPO date?
There is no Nurx IPO date as the company was acquired by Thirty Madison in March 2022. Nurx will not have an IPO since it is now part of Thirty Madison.
How can I buy Nurx stock?
You cannot buy Nurx stock directly as it was acquired by Thirty Madison in 2022. Nurx now operates as part of Thirty Madison's portfolio of digital health brands.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts